All ETDs from UAB

Advisor(s)

Natalia Kedishvili

Committee Member(s)

Chad Petit
Jessy Deshane
Kiril Popov
Nabiha Yusuf

School

Joint Health Sciences (Interdisciplinary)

Document Type

Dissertation

Department (new version)

Biochemistry and Molecular Genetics

Date of Award

9-11-2025

Abstract

Oxylipins represent a structurally diverse class of hydroxylated metabolites generated through the oxidation of polyunsaturated fatty acids (PUFAs), functioning as crucial mediators of various physiological processes. While significant advances have been made in understanding oxylipin biosynthetic pathways, enzymatic mechanisms governing their catabolism remain largely unexplored. This study identified and characterized dehydrogenase reductase 9 (DHRS9), previously described as a retinol dehydrogenase, as a novel oxylipin dehydrogenase. Biochemical analyses demonstrated that DHRS9 functions as a broad-spectrum oxylipin dehydrogenase with pronounced catalytic efficiency toward hydroxylated oxylipins, specifically at carbon positions 12 and above. Furthermore, we generated a Dhrs9(-/-) mouse model and observed significantly diminished oxidative capacity toward oxylipin substrates in lung, tracheal, and skin tissues compared to wild-type (WT) counterparts. Additionally, we evaluated two DHRS9 mutations associated with early-onset epilepsy, revealing substantial impairments in protein stability and enzymatic function. Phenotypic characterization of the Dhrs9(-/-) model established DHRS9's protective role in respiratory tissues, where it attenuated tissue damage and leukocyte infiltration following intranasal lipopolysaccharide (LPS) challenge. Collectively, these findings establish DHRS9 as a clinically relevant oxylipin dehydrogenase capable of modulating inflammatory responses, potentially offering new therapeutic targets for inflammatory disorders.

Available for download on Friday, September 10, 2027

Included in

Biochemistry Commons

Share

COinS